Nexphex Global Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-12-2024
- Paid Up Capital ₹ 0.10 M
as on 05-12-2024
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
About Nexphex Global Pharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Raizada and Rajesh Kumar serve as directors at the Company.
- CIN/LLPIN
U24299UP2021PTC148621
- Company No.
148621
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jul 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Nexphex Global Pharma Private Limited offer?
Nexphex Global Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Anaemia Medicine, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Anti Infective Drugs & Medicines, HIV Drugs, Pharmaceutical Tablets, Antibacterial Drugs, Brain & Nervous System Drugs, Psychotherapeutic Agents.
Who are the key members and board of directors at Nexphex Global Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Raizada  | Director | 12-Jul-2021 | Current |
| Rajesh Kumar | Director | 12-Jul-2021 | Current |
Financial Performance of Nexphex Global Pharma.
Enhance accessibility to Nexphex Global Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nexphex Global Pharma?
Unlock access to Nexphex Global Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nexphex Global Pharma?
Nexphex Global Pharma has a workforce of 0 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexphex Global Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexphex Global Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
